A systematic review of primary Sjögren’s syndrome in male and paediatric populations
- Open Access
- 22.07.2017
- Original Article
Abstract
Introduction
Methods
Search strategy
Study selection
Data extraction
References | Study type | Country of origin | N of pSS patients | Criteria for inclusion of patients | Mean age | Female: male ratio | JBI criteria fulfilled (out of 9) |
|---|---|---|---|---|---|---|---|
Male studies | |||||||
Molina et al. [16] | Cross-sectional study | US | 36 | Personala
| 50 (at diagnosis) | 1.91:1 | 5 |
Anaya et al. [17] | Case-control study | US | 13 | ECSG | 39.4 (at diagnosis) | 2:1 | 4 |
Horvath et al. [18] | Cross-sectional study | Hungary | 60 | AECG | 56.18 (at study) | 7:1 | 6 |
47.83 (at diagnosis) | |||||||
Gondran et al. [19] | Consecutive case series—multicentre study | France | 42 | AECG | 56.9 (at diagnosis) | 10.1:1 | 6 |
Cervera et al. [20] | Consecutive case series study | Spain | 19 | ECSG | 55 (at onset) | 10.7:1 | 5 |
Diaz-Lopez et al. [21] | Cross-sectional study | Spain | 28 | ECSG | 63.5 (at study) | 18.6:1 | 6 |
Drosos et al. [22] | Case selection for male patients, consecutive case series for female patients | Greece | 12 | ECSG | 45.3 (at onset) | 2.5:1 | 5 |
Paediatric studies | |||||||
Yokogowa et al. [23] | Retrospective case-control study | USA | 26 | Personalb
| 12.4 (at diagnosis) | 24:2 | 4 |
Cimaz et al. [24] | Multicentre case series study | Italy | 40 | Personalc
| 10.6 (at onset) | 35:5 | 7 |
Drosos et al. [22] | Case selection for paediatric patients, consecutive case series for female patients | Greece | 13 | ECSG | 9.4 (at onset) | 11:2 | 5 |
Stiller et al. [25] | Retrospective comparative study | Berlin | 11 | EULAR | 9.5 (at onset) | 10:1 | 5 |
Tomiita et al. [26] | Cross-sectional epidemiological study | Japan | 42 | Personald
| 10.7 (at onset) | – | 6 |
Glandular | Extra-glandular (EG) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
References | Dry eyes N (%) | Dry mouth N (%) | Parotitis N (%) | Schirmera
N (%) | Any sicca N (%) | Any EG N (%) | Joint Involvement N (%) | Raynaud’s N (%) | Pulmonary N (%) | Neurological N (%) | Renal N (%) | Lymphadenopathy N (%) | Other N (%) |
Male studies | |||||||||||||
Molina et al. [16] | 14 (38.9) | – | 10 (27.8) | 19 (52.8) | 36 (100)b
| 29 (80.6) | 28 (77.8) | 4 (11.1) | 1 (2.8) | 14 (38.9) | IgA nephropathy—1 (2.8) | 2 (5.6) | Vasculitis—9 (25.0), splenomegaly—3 (8.3), hepatomegaly—3 (8.3), oesophageal dysmotility—3 (8.3), myositis—2 (5.6), |
Anaya et al. [17] | – | – | – | 3 (23.1) | 13 (100) | 12 (92.3) | 6 (46.2) | 3 (23.1) | 1 (7.7) | Total—3 (23.1), CN—1 (7.7), PNS—1 (7,7), CNS—1 (7.7) | GN—1 (7.7) | – | Hepatitis—2 (15.4), non-Hodgkin’s lymphoma—2 (15.4), pancreatitis—1 (7.7), thyroiditis—1 (7.7), myositis—1 (7.7) |
Horvath et al. [18] | – | – | – | – | 60 (100) | – | 41 (68.3) | 4 (6.7) | 0 (0.0) | – | GN/RTA—3 (5.0) | 6 (10.0) | Vasculitis—9 (15.0), serositis—5 (8.3), myositis—5 (8.3) |
Gondran et al. [19] | 38 (90.5) | 40 (95.2) | 15 (35.7) | – | – | 37 (88.1) | 16 (38.1) | 12 (28.6) | 8 (19.0) | 11 (26.2) | 2 (4.8) | 2 (4.8) | Dermatological—9 (21.4), lymphoma—4 (9.5), myositis—4 (9.5), depression—2 (4.8) |
Cervera et al. [20] | 18 (94.7) | 18 (94.7) | 3 (15.8) | – | – | 10 (52.6) | 4 (21.1) | 0 (0.0) | 3 (15.8) | PN—2 (10.5) | – | – | |
Diaz-Lopez et al. [21] | – | – | 5 (17.9) | – | – | – | 8 (28.6) | 5 (17.9) | – | – | – | – | Carpal tunnel syndrome—4 (14.3), fibromyalgia—2 (7.1), thyroidopathy—1 (3.6), liver disease—1 (3.6) |
Drosos et al. [22] | – | – | 2 (16.7) | – | 9 (75.0) | – | 1 (8.3) | 1 (8.3) | – | – | – | 4 (33.3) | Constitutional—4 (33.3), hepatomegaly—2 (16.7) |
Paediatric studies | |||||||||||||
Yokogowa et al. [23] | 16 (61.5) | 17 (65.4) | 16 (61.5) | 6/16 (37.5) | 21 (80.8) | 22 (84.6) | 15 (57.7) | – | – | 6 (23.1) | Total—5 (19.2), nephrocalcinosis—2 (7.7), RTA—2(7.7), nephritis—1 (3.8) | 12 (46.2) | Dental caries—15 (57.7), fever—6 (23.1), haematological—4 (15.3), dermatological—4 (15.3), uveitis—2 (7.7) |
Cimaz et al. [24] | 5 (12.5)c
| 5 (12.5)c
| 29 (72.5)c
| 28 (70.0) | 14 (35.0)c
| – | 4 (10.0)c
| 4 (10.0)d
| – | 2 (5.0) | RTA—3 (7.5)d
| 3 (7.5)d
| Vulvovaginitis—5 (12.5), hepatitis—4 (10.0)d, fever—4 (10.0) c/3 (7.5)d, fatigue—3 (7.5)c
|
23 (57.5)d
| 25 (37.5)d
| ||||||||||||
Drosos et al. [22] | – | – | 10 (76.9) | – | 3 (23.1) | – | 3 (23.1) | 4 (30.8) | – | – | – | 3 (23.1) | Constitutional—3 (23.1), hepatomegaly—1 (7.8) |
Stiller et al. [25] | – | – | 6 (54.5) | 8 (72.7) | – | – | – | – | – | – | – | – | – |
Tomita et al. [26] | – | – | 15 (35.7) | 15 (35.7) | 10 (23.8) | 21 (50.0) | 11 (26.2) | 0 (0.0) | 1 (2.4) | Aseptic meningitis—3 (7.1) | Nephritis—3 (7.1) | 11 (26.2) | Fever—22 (52.4), fatigue—12 (28.6), erythema—11 (26.2), hypothyroidism—2 (4.8), uveitis—2 (4.8), raised AST—1 (2.4), morning stiffness—1 (2.4) |
References | Positive biopsy N (%) | Anti-SSA N (%) | Anti-SSB N (%) | ANA N (%) | RF N (%) | Cryoglobulinaemia N (%) | Other N (%) |
|---|---|---|---|---|---|---|---|
Molina et al. [16] | 29/31 (93.5)a
| 7 (19.4) | 2 (5.6) | 19 (52.8) | 8 (22.2) | – | Raised Ig—7 (19.4) |
Anaya et al. [17] | – | 8 (61.5) | 6 (46.2) | 11 (84.6) | 8/11 (72.7) | 1/9 (11.1) | Lymphopenia—5 (38.5) |
Neutropenia—1 (7.7) | |||||||
Horvath et al. [18] | – | 45 (75.0) | 31 (51.7) | 22 (36.7) | 16 (26.7) | 4 (6.7) | Other ENA—37 (61.6) |
Anti-CCP—9 (15.0) | |||||||
dsDNA—4 (6.7) | |||||||
Anti-thyroglobulin—1 (1.7) | |||||||
Anti-TPO—1 (1.7) | |||||||
Gondran et al. [19] | 42 (100)b
| 21 (50.0) | 14 (33.3) | 32 (76.2) | 22 (52.4) | 8 (19.0) | Raised Ig—20 (47.6) |
Thrombocytopenia—9 (21.4) | |||||||
Lymphopenia—3 (7.1) | |||||||
Leukopenia—1 (2.4) | |||||||
Cervera et al. [20] | – | 3 (15.8) | 3 (15.8) | 13 (68.4) | 5 (26.3) | 1/14 (7.1) | Hypocomplementaemia—0/16 (0.0) |
Diaz-Lopez et al. [21] | – | 7 (25.0) | 4 (14.3) | 22 (78.6) | 13 (46.4) | – | Raised IgA—11 (39.2) |
Raised IgG—7 (25.0) | |||||||
Raised IgM—2 (7.1) | |||||||
Anti-thyroid—2 (7.1) | |||||||
Low IgM—1 (3.5) | |||||||
Drosos et al. [22] | – | 2 (16.7) | 1 (8.3) | 4 (33.3) | 8 (66.7) | – | – |
References | Abnormal sialometry N (%) | Abnormal salivary scintigraphy N (%) | Abnormal ocular stain N (%) | Positive biopsy N (%) | Positive sialography N (%) | Anti-SSA N (%) | Anti-SSB N (%) | Anti-SSA and/or anti-SSB N (%) | Anti-ENA N (%) | ANA N (%) | RF N (%) | Raised ESR N (%) | Raised IgG N (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yokogowa et al. [23] | 5/7 (71.4)a
| 3/3 (100) | 4/16 (25.0) | 10/15 (66.7)b 15/15 (100)c
| – | 22/26 (84.6) | 17/26 (65.4) | 22 (84.6) | – | 25 (96.2) | 16 (72.7) | – | – |
Cimaz et al. [24] | – | 30 (75.0) | – | 40 (100)d
| 40 (100) | – | – | – | 29 (72.5) | 34 (85.0) | 30 (75.0) | 27 (67.5) | 21 (52.5) |
Drosos et al. [22] | – | – | – | – | – | 7 (53.8) | 4 (30.8) | 11 (84.6) | 11 (84.6) | 9 (69.2) | 6 (46.2) | – | – |
Stiller et al. [25] | 9 (81.8)e
| – | 8 (72.7) | 10 (90.9)d
| 10 (90.9) | 4 (36.4) | 3 (27.3) | 7 (63.6) | – | 7 (63.6) | 3 (27.3) | – | 2 (18.2) |
Tomita et al. [26] | – | – | 11 (26.2) | 29 (69.0)f
| 31 (73.8)g
| 26 (61.9) | 13 (31.0) | – | – | 34 (81.0) | 24 (57.1) | – | 32 (76.2) |
Assessment of study quality
Results
Demographics/epidemiological
Clinical features
Glandular features
Extra-glandular features
Laboratory features
Discussion
Significance and innovation
-
This is the first systematic review of pSS in rare populations
-
Large, multicentre, good-quality studies of pSS in rare populations and classification criteria for pSS in paediatric population are lacking
-
Children with pSS have less dryness, and more frequently experienced systemic symptoms and parotid enlargement
-
There were no consistent differential features of male pSS patients when compared to adult female patient population